Enlivex Therapeutics 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Oren Hershkovitz

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	5yrs
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Oren Hershkovitz 의 보수는 Enlivex Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$22m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	n/a	n/a	-US$29m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	n/a	n/a	-US$31m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$26m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$12m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$296k	US$38k	-US$10m

보상 대 시장: IL 시장에서 비슷한 규모의 회사에 비해 Oren 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Oren 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Oren Hershkovitz (47 yo)

5yrs

테뉴어

US$295,600

보상

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Shai Novik	Executive Chairman	10.8yrs	US$536.00k	3.62% ₪ 2.7m
Oren Hershkovitz	Chief Executive Officer	5yrs	US$295.60k	0.12% ₪ 87.8k
Shachar Shlosberger	Chief Financial Officer	8.8yrs	US$132.00k	0.0088% ₪ 6.5k
Veronique Amor-Baroukh	Senior Director of Operations	2.8yrs	데이터 없음	데이터 없음
Sigal Arad	Director of HR	2.8yrs	데이터 없음	데이터 없음

5.0yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: ENLV 의 관리팀은 노련하고 경험 (평균 재직 기간 5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shai Novik	Executive Chairman	10.8yrs	US$536.00k	3.62% ₪ 2.7m
Andrew Singer	Independent Director	1.6yrs	데이터 없음	데이터 없음
Abraham Havron	Independent Director	10.8yrs	데이터 없음	0.85% ₪ 624.2k
Mitchell Levy	Clinical Advisor	no data	데이터 없음	데이터 없음
Roger Pomerantz	Independent Vice Chairman of the Board	2.5yrs	데이터 없음	0% ₪ 0
Brian Schwartz	Director	3.9yrs	데이터 없음	0.013% ₪ 9.4k
Clifford Deutschman	Clinical Advisor	no data	데이터 없음	데이터 없음
David Hunter	Clinical Advisor	less than a year	데이터 없음	데이터 없음
Bruno Francois	Clinical Advisor	less than a year	데이터 없음	데이터 없음
Gili Hart	Independent Director	10.8yrs	데이터 없음	0.024% ₪ 17.4k
Ali Mobasheri	Clinical Advisor	less than a year	데이터 없음	데이터 없음
Tobias Winkler	Clinical Advisor	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: ENLV 의 이사회는 경험(평균 재직 기간 2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Enlivex Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Recent updates

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

New major risk - Revenue and earnings growth

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

New major risk - Financial position

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Insufficient new directors

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

Enlivex Therapeutics Ltd.: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Enlivex Awards Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Enlivex Therapeutics Ltd Receives Notice of Allowance for Japanese Patent Application

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Announces Issuance of U.S. Patent No. 10,927,343 Covering AllocetraTM, the Immunotherapy Product Candidate

Enlivex Therapeutics Ltd. Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update

New 90-day high: ₪43.50

Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on Medrxiv

Enlivex Therapeutics Ltd Reports Positive Interim Results of an Investigator-Initiated Phase Ii Clinical Trial Evaluating Allocetratm in Severe and Critical Covid-19 Patients

Enlivex Therapeutics Ltd. Reports Positive Two-Year Clinical Outcome for Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

Enlivex Appoints Dr. Brian Schwartz to the Board of Directors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Reports That the Israeli Ministry of Health Authorized the Initiation of a Proposed Investigator-Initiated Phase II Clinical Trial Evaluating AllocetraTM in Severe and Critical COVID-19 Patients

Enlivex Therapeutics Ltd Reports Positive Top-Line Results of an Investigator-Initiated Clinical Trial of Allocetratm in COVID-19 Patients in Severe/Critical Condition

New 90-day high: ₪33.21

Enlivex Therapeutics Ltd. Receives New Patent Application Covering ALLOCETRA™

New 90-day low - ₪15.84

New 90-day low - ₪16.80

CEO 보상 분석

CEO